Back

Tiered royalties reach 60% of 2026 pharma licensing deals

Verifying
  • ResearchAndMarkets.com added a report benchmarking pharmaceutical and biotechnology licensing royalty rates.
  • Sixty percent of qualifying 2026 deals used tiered royalties, versus around four in ten in 2020.
  • The report covers more than 1,600 disclosed transactions announced from January 2015 through August 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.